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Abstract 
Purpose: To assess the role of 3'-deoxy-3'-18F-fluoro-thymidine (18F-FLT) and 2'-deoxy-2'-18F-fluoro-
deoxy-glucose (18F-FDG)  positron emission tomography (PET) imaging in the evaluation of the 
therapeutic effects of radiotherapy during treatment of lung adenocarcinoma.  
Methods: Eighteen mice with lung adenocarcinoma were randomly divided into 2 groups; each group 
was randomly paired and evenly divided into three smaller groups, namely, A, B and C. Group A served 
as the control group without any treatment; mice in group B were received radiotherapy in sites of 
tumor. A single dose of 2000 cGy, 6MV x-ray was used in this experiment; mice in group C also 
received radiotherapy at sites of tumors two days before the experiment using the same procedure and 
dose as group B. Micro PET imaging was taken after intravenous injection of 18F-FLT and 18F-FDG 
through the mice’s tail. 
Results: The intake ratio of 18F-FLT and 18F-FDG was much higher at the tumor sites. After 
radiotherapy, 18F-FLT uptake was significantly lower than that of the control group (p < 0.05), while 
there was no obvious change of 18F-FDG uptake. There was a significant decrease in T/NT value of FLT 
PET imaging group 24 and 48 h after radiotherapy; a significant difference could be seen, compared 
with that before radiotherapy (p < 0.05). 
Conclusion: Change in 18F-FLT uptake induced by radiotherapy is more sensitive than that of 18F-FDG. 
Intake of 18F-FLT is lowered more significantly after radiotherapy than that of 18F-FDG, and this can 
serve as evidence that 18F-FLT is an effective tracer to monitor the therapeutic effect of radiotherapy on 
malignant tumors.  
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Positron emission tomography (PET) is a rapidly 
developing imaging technology in recent years, 
which has significantly benefited the diagnosis, 
staging and especially the therapeutic effect 
evaluation of radiotherapy for malignant tumors 
[1-4]. 18F-FDG is the most commonly-used tracer 
in PET-CT clinical examination, but there may be 
some false positives since 18F-FDG is not a 
tumor-specific tracer and can be ingested by 
inflammatory cells, granulation tissue, etc. 18F-
FLT, the derivative of thymidine, has drawn a lot 
of attention because it can reflect the value-
added features of tumors [5,6]. 
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The purpose of this study was to assess the bio-
distribution regularity of 18F-FLT in mice and the 
feasibility of PET imaging by constructing the 
lung adenocarcinoma model of tumor-bearing 
mice; mice with lung adenocarcinoma were 
treated with radiotherapy. The role of 18F-FDG 
and 18F-FLT in monitoring the therapeutic effects 
of radiotherapy treated lung adenocarcinoma 
was evaluated by comparing the changes of PET 
imaging of tumor ingesting 18F-FDG and 18F-FLT 






Six-week old Balb/c-nu mice, weighing 18 to 20 
g, half male and female, provided by 
Experimental Animal Center of PLA General 
Hospital, were reared in the laminar flow racks in 
the Experimental Animal Center of PLA General 
Hospital according to the Specific Pathogen Free 
(SPF) standard. Experimental animal use 
certificate issued is no. 2006E00699.  
 
Tracers: 3-deoxy -3-18F-fluoro-thymidine (18F-
FLT) and 18F-fluoro-deoxy-glucose (18F-FDG) 
provided by the Nuclear Medicine PET 
Laboratory of People's Liberation Army General 
Hospital. FT603 well-type detector was made by 
Beijing 261 Factory. PET imaging system: 
eXplore VISTA-CT MicroPET/CT, GE, made in 
USA. Linear accelerator: Swedish Elekta Precise 
linear accelerator. Tumor lines: A549 human lung 
adenocarcinoma cell line, provided by the 
Cancer Institute of Chinese Academy of Medical 
Sciences Test solution: DMEM medium (Gibco, 
USA), RPMI-1640 medium (Gibco, USA), fetal 
bovine serum (Huamei biological preparation 
company) and trypsin (Sigma, USA). 
 
Establishment of tumor-bearing mice model 
 
Single cell suspension (2 × 105/mL) was 
conventionally prepared using the normal sub-
cultured A-549 tumor cell line of lung 
adenocarcinoma, 0.2 mL of which was taken and 
subcutaneously inoculated in the right armpit of 
the mice. The subcutaneous inoculations of the 
mice resulted in tumors whose diameters ranged 
from 1.0 to 1.2 cm. The experiment was 
performed in 6 or 7 days after inoculation. 
  
18F-FDG and 18F-FLT PET imaging 
 
The tumor-bearing mice were randomly and 
evenly divided into the FDG group and FLT 
group of 3. The two groups were injected with 0.2 
mL 18F-FLT (3.7 MBq) and 0.2 mL 18F-FDG (3.7 
MBq) respectively via the tail veins. PET imaging 
and determination of bio-distribution measure 
were carried out in 60 min after the injection.  
 
After being anaesthetized with 2 mL of 10 % 
chloral hydrate, the mice were laid on the micro 
PET/CT beds, with limbs fixed with tape, and 
were scanned for 10min. The 3D mode was used 
to capture images. The scanning results were 
analyzed by dispersed and random counting and 
reconstruction of the cross-sectional images of 
the coronal plane, transverse section and sagittal 
plane. 
 
Image data analysis 
 
The software package of MicroPET/CT 
acquisition system was used to analyze the 
image data. A region of interest (ROI) was 
outlined in the best level of tumor selected in the 
image. A ROI of the same size was outlined in 
the contralateral tumor-free area as a control. 
The average count value and standard 
deviations were recorded within the ROI with the 
unit of value/pix. The T/NT value was calculated. 
 
Evaluation of the therapeutic effect of 
radiotherapy  
 
Eighteen mice with lung adenocarcinoma were 
randomly divided into 18F-FLT group and 18F-
FDG goups and then each group was randomly 
paired and evenly divided into three smaller 
groups, namely, group A, B and C. Group A 
served as the control group without any 
treatment; group B were anaesthetized with 
isoflurane one day before the experiment, and 
then received radiotherapy in sites of tumors 
while being placed under fixed linear accelerator.  
 
A single dose of 2000 cGy, 6 MV energy and x-
ray were used in this experiment; mice in group 
C also received radiotherapy two days before the 
experiment in sites of tumors with the same 
methods and radiotherapy dose as group B. 
Methods of microPET/CT imaging of the tumor-
bearing mice and image data analysis were 




For statistical analysis, SPSS 12.0 statistical 
software was used to carry out t-test and 
correlation analysis of the mean of two groups. P 
< 0.05 was considered statistically significant. 
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In vivo biodistribution and PET imaging  
 
Biodistribution of two tracers in tumor-
bearing mice 
 
The tumor-bearing mice both in the FLT group 
and the FDG group were killed 60 min after 
injection, and their organs and tissues were 
separated to detect radioactive distribution 
(Table 1). The radioactive uptake of the FLT 
group was significantly lower than that of the 
FDG group. Tissues or organs with the highest 
radioactive uptake were, in order of the heart, 
tumor and kidney; except for heart and kidney, 
the T/NT values of tumors to other normal 
tissues were all greater than 2. Organs or tissues 
of the FDG group with the highest radioactivie 
uptake were, in order of the kidney, tumors, 
spleen and liver; except for the first three, the 
T/NT values of tumors to other normal tissues 
were all greater than 2. There was a significant 
difference (p < 0.05) between the two groups’ 
T/NT values of tumors to heart, liver and kidney. 
 
After comparing the biodistribution of the two 
tracers in tumor-bearing mice, it could be seen 
that in the FDG group, except for heart and  
kidney, the T/NT values of tumors to other 
normal tissues were all greater than 2; in the 
FDG group; except for kidney, spleen and liver, 
the T/NT values of tumors to other normal 
tissues were all greater than 2. There was a 
significant difference between the two groups’ 
T/NT values of tumors to heart, liver and kidney 
(p < 0.05). 
 
Moreover, PET imaging was made in the FLT 
group and FDG group, 60 min after injection. 
After being processed by the software package 
of microPET/CT acquisition system, it could be 
seen that the tumor uptake was significantly 
higher than before. A region of interest (ROI) was 
outlined in the best level of tumor in the image 
and another ROI of the same size was outlined in 
the contralateral tumor-free area as a control. 
The average count value and standard 
deviations were recorded within the ROI with the 
unit of value/pix. There were significant 
differences between the T/NT values of FLT 
group and FDG in 60 min after the injection (FLT 
2.4 ± 0.2, FDG 4.3 ± 0.3, p < 0.05). 
 
MicroPET imaging (coronal plane) of 18F-FLT in 
mice with lung adenocarcinoma 60 min after 
injection showed that tumors inoculated in the left 
forelimbs of mice were evenly assimilated. 
MicroPET imaging (coronal plane) of 18F-FDG in 
mice with lung adenocarcinoma 60 min after 
injection showed that tumors inoculated in the left 
forelimbs of mice had significant uptake. Tumor 
necrosis could be seen in intratumoral areas with 
low intake. 
 
Therapeutic effect of radiotherapy  
 
Tumor % ID/g of the two tracers in tumor-bearing 
mice of the two groups are shown in Table 2. In 
the radiation experiments, six groups of mice 
with two tracers were killed 60 min after injection. 
The well-type detector was used to detect the 
radioactivity distribution (% ID/g) of tumors. The 
tumor tissue % ID/g of group B and group C, 
which were treated with radiotherapy in FDG 
group, decreased a little bit more than that of the 
control group (A), but there was no significant 
statistical difference (p > 0.05), while the tumor 
tissue % ID/g of group B and group C in the FLT 
group, decreased much more significantly when 
compared with group A. The difference between 
them was statistically significant (p < 0.05). 
 
The tumor tissue % ID/g of group B and group C 
in the FDG group, decreased a little bit more 
than that of the control group A after 
radiotherapy, but it was of no significant 
statistical difference (p > 0.05). 
 
Table 1: Comparison of the biodistribution of the two tracers in lung adenocarcinoma models (mean±SD) 
 
Organ %ID/g T/NT FDG group FLT group FDG group FLT group 
Heart 26.77±5.45 0.49±0.12 0.38±0.11 3.21±1.15* 
Liver 2.17±0.48 0.69±0.11 4.65±1.39 2.27±0.56* 
Spleen 4.43±0.63 0.87±0.12 2.25±0.75 1.80±0.42 
Lung 4.29±0.71 0.61±0.15 2.35±0.63 2.58±0.71 
Kidney 5.27±1.15 1.55±0.21 1.92±0.47 1.03±0.21* 
Muscle 3.09±0.49 0.51±0.17 3.27±0.89 3.11±0.85 
Tumor 10.11±2.11 1.57±0.43   
*There is statistical difference between the two groups (p < 0.05) 
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Table 2: Tumor (% ID/g) of tumor-bearing mice in each group (mean±SD) 
 
 Group A Group B Group C 
FDG group 10.24±1.73 8.73±1.71 7.97±1.15 
FLT group 1.41±0.38 0.71±0.08* 0.33±0.07* 
* Statistical difference could be seen when compared with group A (P < 0.05) 
 
Tumor tissue % ID/g of group B and group C in 
the FLT group decreased much more 
significantly than that of group A after 
radiotherapy. The difference between them was 
statistically significant (p < 0.05).  
 
From PET imaging of tumor-bearing mice in the 
FLT and FDG groups in 24 h and 48 h after 
radiotherapy and the PET imaging of those in 
control groups, it can be seen that FLT and FDG 
uptake of tumors were both high before 
radiotherapy and theT/NT values of the control 
group and radiotherapy group were not 
statistically different in 0 h. The T/NT value of the 
FDG group was higher than that of the FLT 
group. The T/NT values of the FLT group 
decreased significantly 24 h and 48 h after 
radiotherapy and there was a significant 
difference when compared with that before 
radiotherapy (3.3 ± 0.5, 1.7 ± 0.3, 1.2 ± 0.2, p < 
0.05), while no significant differences of the T/NT 
values could be seen in the  control group (p > 
0.05). There was a significant difference between 
the T/NT values of the control group and the 
radiotherapy group 24 h and 48 h of radiotherapy 
(p < 0.05), while it was of no significant 




Early evaluation of anti-tumor therapy is of great 
importance for the assessment of the therapeutic 
scheduled screening and prognosis of diseases. 
Presently, the clinical evaluation of anti-tumor 
efficacy is mainly achieved by radiographic 
techniques, which can determine the effects of 
treatment by early observation of the changes of 
tumor size before and after the treatment. 
However, a series of biological development 
process is involved in the changes of tumor size. 
The changes of tumor size can not only be 
caused by changes in tumor cell proliferation, but 
can also be induced by other factors, such as 
tissue fibrosis, inflammatory cell infiltration and 
changes in tissue fluid. 
 
In addition, some new anticancer drugs which 
can inhibit the development of tumors instead of 
killing tumor cells, cannot change the size of 
tumor. Therefore, general radiological imaging 
techniques can only indirectly reflect the 
functional status of the tumor tissue and have 
some flaws in the evaluation of anti-tumor 
therapy efficacy. 
 
Positron emission tomography (PET), which has 
been widely used, can noninvasively detect the 
positron radionuclide distribution in the body and 
reflect the physiological, pathological, 
biochemical, and metabolic changes in human 
tissues at the molecular level. PET imaging, 
which can sensitively and accurately reflect the 
abnormal conditions of tumor perfusion, 
metabolism, protein synthesis, DNA replication 
and cell proliferation, is an effective tool of tumor 
diagnosis and anti-tumor efficacy evaluation 
[5,6]. 
 
The radioactive tracers used in PET imaging are 
mainly drugs labeled by "organic" positron 
emitters, including 11C, 13N, 15O, and 18F, which 
can be divided into categories of metabotropic 
tracer, bound tracer and blood perfusion tracer 
etc., according to their biochemical function. The 
development of PET, to some extent, depends 
on the development and application of positron 
tracer. Moreover, 18F-fluoro-deoxy-glucose (18F-
FDG) is the most widely used tracer up to now, 
whose biological behavior is similar to that of 
glucose. It is taken up and phosphorylated by 
cells via the same pathway as glucose and is 
stranded in mitochondria due to the failure of 
further metabolism. Influenced by local hypoxia 
and changes of tumor biological behavior, a 
significantly increased protein expression of 
glucose transporter and highly active glycolysis 
can be seen in malignant tumor cells. Therefore, 
the uptake and retention of 18F-FDG in tumor 
tissue is several or even dozens of times higher 
than that in normal tissues.  
 
However, 18F-FDG is not a tumor-specific tracer. 
It can result false positives [7], since it can also 
be ingested by inflammatory cells, and granular 
tissues. In recent years, nucleoside metabolic 
PET tracers have made significant progress. 
Currently, 3'-deoxy-3'-18F-fluoro-thymidine, 18F-
FLT is the most promising nucleoside metabolic 
tracer, which can indirectly reflect the state of 
tumor cell proliferation by interacting with the key 
enzyme, thymidine kinase -1 in the DNA 
synthesis and salvage pathway, in order to 
specifically diagnose tumors [8]. The 
biodistribution and PETimaging of 18F-FLT and 
18F-FDG in models of mice with lung 
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adenocarcinoma were compared and studied in 
this experiment.  
 
It was observed that although % ID/g of the FLT 
group was significantly lower than that of the 
FDG group, the radioactivity uptake of tumors in 
both groups were relatively high; T/NT values of 
tumors to heart, lungs and muscles in FLT group 
were greater than 2; a significantly radioactive 
hot zone of the tumor issues could be seen in the 
PET imaging, which was quite clear and 
consistent with the detection results of % ID/g 
obtained by the well-type detector. It can be 
concluded that 18F-FLT, which can clearly 
distinguish tumor tissues from other normal 
tissues, can be applied in the PET imaging of 
lung malignant tumors. Its low background in 
heart enables it to make up the inadequacies of 
18F-FDG as a tracer. It can better distinguish 
breast tumor from mediastinal metastases to 
further improve the efficiency of clinical diagnosis 
and staging. 
 
The impacts of radiotherapy on 18F-FDG uptake 
is complex [9], since the repair mechanism 
activation of cell damages induced by radiation, 
causes stenosis and occlusion of tumor vessels 
occurring after radiotherapy and the hypoxia 
caused by swelling and edema of tumor tissues, 
can all lead to the increase of 18F-FDG uptake by 
starting pathways of anaerobic glycolysis and 
aerobic oxidation, but the proliferation of tumor 
cells was inhibited, so it is difficult for 18F-FDG to 
reflect the therapeutic effects accurately. 
 
Although there are a large number of reports on 
application of 18F-FDG in evaluation of antitumor 
efficacy [10], 18F-FDG can mainly reflect the in 
vivo glucose utilization, instead of detecting 
tumor reactions specifically, while 18F-FLT can 
better reflect the therapeutic effects of tumors 
when applied to measure changes of tumor 
proliferation activity. 
 
In this study, radiotherapy intervention was made 
on mice with lung adenocarcinoma. The uptake 
and PET imaging of the two tracers in tumors 
before and after radiotherapy were compared 
and analyzed. A rapid decrease of tumor tissue 
% ID/g could be found in the FLT group in 24 h 
and 48 h after radiotherapy, which was of 
significant statistical difference compared with 
the control group; while there was no significant 
difference between the % ID/g values of the FDG 
radiotherapy group and control group. PET 
imaging of tumor tissues of tumor-bearing mice 
in FLT control group was clear. The T/NT values 
of the FLT group decreased significantly in 24 h 
and 48 h after radiotherapy and there was a 
significant difference when compared with the 
one before radiotherapy while no significant 
differences of the T/NT values could be seen in 
the control group. There was a significant 
difference between the T/NT values of the control 
group and the radiotherapy group in 24 h and 48 
h of radiotherapy, while it was of no significant 
difference in the FDG group. It can be seen that 
18F-FLT is also able to monitor early the effects 
of radiotherapy in treating tumors noninvasively, 
which enables the implementation of a much 




Both 18F-FLT and 18F-FDG, can serve as suitable 
lung cancer PET tracers. Compared with 18F-
FDG, 18F-FLT is more sensitive in capturing the 
early reactions of tumors during radiotherapy. It 
significantly correlates with tumor proliferation 
activity and can provide accurate biological 
information for the assessment of therapeutic 
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